Metraipolis › archive › dc_a016d50bdc83
Durvalumab consolidation therapy in patients with stage III small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis — Europe PMC PMID:41267974
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41267974
- DOI
- 10.3389/fonc.2025.1643022
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T18:39:54.208Z
- SHA-256 of the archived text
991ca8b893db9dd837f8226758af2725872649631d2d271a7137de21b17bf0cc- Stable URL of this page
https://metraipolis.com/documento/dc_a016d50bdc83
How to cite
Durvalumab consolidation therapy in patients with stage III small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis — Europe PMC PMID:41267974 — Europe PMC (en), https://europepmc.org/article/MED/41267974 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a016d50bdc83 (Metraipolis archive dc_a016d50bdc83, sha256 991ca8b893db9dd837f8226758af2725872649631d2d271a7137de21b17bf0cc)
BibTeX
@misc{dca016d50bdc83,
title = {Durvalumab consolidation therapy in patients with stage III small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis — Europe PMC PMID:41267974},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41267974},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a016d50bdc83; sha256 991ca8b893db9dd837f8226758af2725872649631d2d271a7137de21b17bf0cc},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41267974. Agents can read the archived copy with the MCP tool read_document.